These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 21960216

  • 1. A fluorescence polarization assay for the discovery of inhibitors of the polo-box domain of polo-like kinase 1.
    Reindl W, Strebhardt K, Berg T.
    Methods Mol Biol; 2012; 795():69-81. PubMed ID: 21960216
    [Abstract] [Full Text] [Related]

  • 2. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
    Reindl W, Strebhardt K, Berg T.
    Anal Biochem; 2008 Dec 15; 383(2):205-9. PubMed ID: 18793607
    [Abstract] [Full Text] [Related]

  • 3. Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3.
    Reindl W, Gräber M, Strebhardt K, Berg T.
    Anal Biochem; 2009 Dec 15; 395(2):189-94. PubMed ID: 19716361
    [Abstract] [Full Text] [Related]

  • 4. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
    Chen Y, Zhang J, Li D, Jiang J, Wang Y, Si S.
    Oncotarget; 2017 Jan 03; 8(1):1234-1246. PubMed ID: 27902479
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
    Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.
    Chem Biol; 2008 May 03; 15(5):459-66. PubMed ID: 18482698
    [Abstract] [Full Text] [Related]

  • 6. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
    Berg A, Berg T.
    Chembiochem; 2016 Apr 15; 17(8):650-6. PubMed ID: 26662918
    [Abstract] [Full Text] [Related]

  • 7. Development of a High-Throughput Assay for Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1 Based on Time-Resolved Fluorescence Energy Transfer.
    Kim TG, Lee JH, Lee MY, Kim KU, Lee JH, Park CH, Lee BH, Oh KS.
    Biol Pharm Bull; 2017 Apr 15; 40(9):1454-1462. PubMed ID: 28867728
    [Abstract] [Full Text] [Related]

  • 8. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
    Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.
    Chembiochem; 2009 May 04; 10(7):1145-8. PubMed ID: 19350612
    [Abstract] [Full Text] [Related]

  • 9. Pinning down the polo-box domain.
    Lee KS, Idle JR.
    Chem Biol; 2008 May 04; 15(5):415-6. PubMed ID: 18482691
    [Abstract] [Full Text] [Related]

  • 10. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
    Shan HM, Shi Y, Quan J.
    ChemMedChem; 2015 Jan 04; 10(1):158-63. PubMed ID: 25196850
    [Abstract] [Full Text] [Related]

  • 11. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
    Scharow A, Knappe D, Reindl W, Hoffmann R, Berg T.
    Chembiochem; 2016 Apr 15; 17(8):759-67. PubMed ID: 26634982
    [Abstract] [Full Text] [Related]

  • 12. Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1.
    Richter S, Neundorf I, Loebner K, Gräber M, Berg T, Bergmann R, Steinbach J, Pietzsch J, Wuest F.
    Bioorg Med Chem Lett; 2011 Aug 15; 21(16):4686-9. PubMed ID: 21778054
    [Abstract] [Full Text] [Related]

  • 13. Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands.
    Elling RA, Fucini RV, Romanowski MJ.
    Acta Crystallogr D Biol Crystallogr; 2008 Sep 15; 64(Pt 9):909-18. PubMed ID: 18703838
    [Abstract] [Full Text] [Related]

  • 14. Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay.
    Normandin K, Lavallée JF, Futter M, Beautrait A, Duchaine J, Guiral S, Marinier A, Archambault V.
    Sci Rep; 2016 Nov 22; 5():37581. PubMed ID: 27874094
    [Abstract] [Full Text] [Related]

  • 15. Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds.
    Abdelfatah S, Fleischer E, Klinger A, Wong VKW, Efferth T.
    Invest New Drugs; 2020 Feb 22; 38(1):1-9. PubMed ID: 30877426
    [Abstract] [Full Text] [Related]

  • 16. Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
    Zhong H, Xin S, Zhao Y, Lu J, Li S, Gong J, Yang Z, Lin S.
    Mol Biosyst; 2010 Aug 22; 6(8):1463-8. PubMed ID: 20625580
    [Abstract] [Full Text] [Related]

  • 17. Selectivity-determining residues in Plk1.
    Kothe M, Kohls D, Low S, Coli R, Rennie GR, Feru F, Kuhn C, Ding YH.
    Chem Biol Drug Des; 2007 Dec 22; 70(6):540-6. PubMed ID: 18005335
    [Abstract] [Full Text] [Related]

  • 18. Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1.
    Chen Y, Li Z, Liu Y, Lin T, Sun H, Yang D, Jiang C.
    Bioorg Chem; 2018 Dec 22; 81():278-288. PubMed ID: 30170276
    [Abstract] [Full Text] [Related]

  • 19. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
    Park JE, Kim TS, Kim BY, Lee KS.
    Cell Cycle; 2015 Dec 22; 14(22):3624-34. PubMed ID: 26513691
    [Abstract] [Full Text] [Related]

  • 20. Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators.
    Archambault V, Normandin K.
    Cell Cycle; 2017 Jun 18; 16(12):1220-1224. PubMed ID: 28521657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.